Microbot Medical Inc. announced on February 10, 2025, that it has entered into definitive agreements for a registered direct offering expected to generate approximately $13 million in gross proceeds. The offering includes the purchase and sale of 6,103,289 shares of common stock at $2.13 per share.
In a concurrent private placement, the company will issue unregistered short-term series I preferred investment options. These options allow for the purchase of up to 12,206,578 shares of common stock at an exercise price of $2.13 per share, exercisable for two years following stockholder approval.
The net proceeds from these offerings are intended to support the continued development, commercialization, and regulatory activities for the LIBERTY Robotic System. Funds will also be allocated for the expansion of additional applications from the company's existing IP portfolio, as well as for working capital and general corporate purposes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.